Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com
Venetoclax Shows Impressive Activity in Relapsed/Refractory Waldenström Macroglobulinemia
January 19th 2022Venetoclax proved to be safe and highly active when used in patients with relapsed or refractory Waldenström macroglobulinemia, including those who previously received BTK inhibitors and those harboring CXCR4 mutations.
Read More
Luspatercept Under Exploration in Myeloproliferative Neoplasm–Associated Myelofibrosis
January 17th 2022The safety and efficacy of luspatercept vs placebo is under exploration in patients with myeloproliferative neoplasm–associated myelofibrosis who are receiving concomitant JAK2 inhibitor therapy and who require red blood cell transfusions, as part of the phase 3 INDEPENDENCE trial.
Read More
Pembrolizumab Elicits Robust, Durable Antitumor Activity in MSI-H Advanced Endometrial Cancer
January 17th 2022Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.
Read More
Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia
January 14th 2022Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke.
Read More
Zilovertamab Plus Ibrutinib Under Further Evaluation in Relapsed/Refractory MCL
January 12th 2022The FDA has agreed upon key elements, including design features and operational details, for the phase 3 ZILO-301 trial, which will evaluate zilovertamab in combination with ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
Read More
CLN-081 Continues to Elicit Encouraging, Durable Responses in EGFR Exon 20 Insertion+ NSCLC
January 6th 2022CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.
Read More
FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC
January 6th 2022The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Read More
The combination of tumor-infiltrating lymphocyte cell therapy with lifileucel or LN-145 and pembrolizumab demonstrated encouraging efficacy and safety in patients with advanced melanoma, head and neck squamous cell carcinoma, and cervical cancer who were naïve to immune checkpoint inhibitors.
Read More
Addition of Lenalidomide to Rituximab Maintenance Improves PFS in Elderly Patients With MCL
December 21st 2021The addition of lenalidomide to rituximab maintenance treatment significantly improved progression-free survival compared with rituximab alone following first-line chemoimmunotherapy in patients with mantle cell lymphoma.
Read More
Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes
December 16th 2021Itolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem cell transplantation, and improve outcomes for these patients.
Read More
Cilta-Cel Produces Deep Responses as Second-Line Treatment in Early Relapse Myeloma
December 13th 2021A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.
Read More
Cilta-cel Shows Greater Clinical Benefit Than SOC in Triple-Class Relapsed/Refractory Myeloma
December 12th 2021Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.
Read More
Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma
December 11th 2021The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
Read More
Tucatinib Plus Palbociclib/Letrozole Prolongs CNS-PFS in HR+/HER2+ Breast Cancer
December 8th 2021A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.
Read More
Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL
December 3rd 2021Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.
Read More
CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors
November 23rd 2021AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.
Read More
Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets
November 12th 2021The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.
Read More
Trilaciclib Possesses Potential to Reduce Burden of Chemotherapy-Induced Myelosuppression in ES-SCLC
November 11th 2021The administration of trilaciclib prior to chemotherapy reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with extensive-stage small cell lung cancer.
Read More